A Randomised Phase 2 Trial of Pemetrexed and Gefitinib Versus Gefitinib as First Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Pemetrexed (Primary) ; Gefitinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 16 Jan 2018 Status changed from active, no longer recruiting to completed.
- 25 Aug 2017 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
- 11 Oct 2016 Results of translational research, interim overall survival data and safety data presented at the 41st European Society for Medical Oncology Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History